About Us
The Center for Chemical Genomics provides high-throughput screening of extensive small molecule, natural product and siRNA libraries — along with assay development and optimization — for basic biology and drug discovery projects.
Our dedicated staff has years of experience in academic drug discovery and within the pharmaceutical industry, allowing us to provide expert guidance to researchers through every stage of a project.
Our services are available to U-M researchers and to outside academic and industry partners.
If you're a new user, please visit our getting started guide.
Our Services
We offer high-throughput screening of extensive small molecule, natural product and siRNA libraries — along with assay development and optimization — for basic biology and drug discovery projects.
We have more than 250,000 diverse small molecule compounds, a unique library of more than 45,000 natural product extracts, an extensive siRNA library and a growing library of 7,000-plus FDA-approved drugs and clinical compounds for drug repurposing projects.
Explore MScreen, a cost-effective, web-based data storage and analysis tool we developed to help users streamline the hit-to-lead decision process.
Grant Assistance
Download an editable letter of support and resource descriptions to support your grant submission.
Publication Acknowledgments
Please remember to acknowledge the center in research publications that relied on our services.
Featured News
New research clarifies how ‘fuzzy’ proteins can be used to develop novel drugs
Researchers have determined how to target a class of proteins that have long been considered too “fuzzy” to target with small molecules, opening the door to new drug-discovery projects.
Michigan Medicine enters drug discovery collaboration with AstraZeneca in Chronic Kidney Disease
Patients with Chronic Kidney Disease may benefit from a new collaboration between U-M and AstraZeneca, who have partnered to develop a new therapeutic strategy for treatment.
Repurposed asthma drug shows blood sugar improvement among some diabetics
After 12 weeks of taking an anti-asthma drug, a subset of patients with type 2 diabetes showed a clinically significant reduction in blood glucose during a clinical trial.